Martin E. Gutierrez, MD, discusses data for Dato-DXd plus rilvegostomig in advanced or metastatic NSCLC.
Martin E. Gutierrez, MD
Advertisement
Articles by Martin E. Gutierrez, MD
Martin E. Gutierrez, MD, discusses the investigation of MK-0482 in advanced solid tumors.
Martin E. Gutierrez, MD, director, co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the safety profile of pembrolizumab (Keytruda)-based combination strategies in non-small cell lung cancer (NSCLC).
Martin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.
Advertisement
Latest Updated Articles
Dr. Gutierrez on Biomarker-Directed Precision Oncology of Pembrolizumab-Based Combos in NSCLCPublished: June 28th 2019 | Updated:
Dr. Gutierrez on the Safety Profile of Pembrolizumab-Based Combos in NSCLCPublished: January 31st 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5